Omics-Insights: Your Weekly Genomics & Proteomics Digest
Tom Jones | Head of Omics Division at Kinetica | 19th April 2024

Omics-Insights: Your Weekly Genomics & Proteomics Digest

Greetings, Omics Enthusiasts!

Welcome to our latest Omics Newsletter, your portal to the freshest updates and innovations in genomics. This week's newsletter brings you the latest updates from the dynamic world of Omics. In this week's newsletter, Telesis Bio Inc. takes the spotlight as it redirects its strategic focus towards leveraging its groundbreaking Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions for high-throughput drug discovery applications. Meanwhile, Bruker's acquisition of NanoString Technologies for approximately $392.6 million in cash marks a significant development in the spatial biology market. Illumina introduces the TruSight One Sequencing Panel, boasting the industry's most expansive sequencing panel to date, targeting 4,813 genes known for their associated clinical phenotypes. Vizgen secures a new US Patent for its MERFISH technology, reinforcing its position as a leader in single-cell spatial genomics. Also, spotlighting Dr. Dan Gibson, Co-Founder of Telesis Bio, revolutionizing drug discovery with enzymatic synthesis. Explore current live Omics roles at Kinetica and gain valuable job-hunting tips from an Omics specialist recruiter.


This week's latest news in the field of Omics:

Telesis Bio Shifts Strategic Focus

Telesis Bio Inc., known for its automated benchtop DNA and mRNA synthesis solutions, is redirecting its strategic focus towards leveraging its groundbreaking Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions. The company aims to drive the adoption of the Gibson SOLA platform for high-throughput drug discovery applications, particularly in mRNA synthesis through the BioXp automation platform. Telesis Bio believes its Gibson SOLA platform offers unparalleled advantages over existing solutions, enabling rapid synthesis of high-fidelity synthetic oligonucleotides, genes, and transfection-ready mRNA at various scales, sometimes overnight. This accelerated synthesis capability promises to significantly reduce the time needed for researchers to identify, screen, and optimize complex constructs, providing more consistent and reliable results.

Bruker Acquisition of NanoString Technologies, Inc.

Bruker's acquisition of NanoString Technologies for approximately $392.6 million in cash marks a significant development in the spatial biology market. With NanoString's assets under its belt, Bruker expands its presence and capabilities in this sector, following previous investments in spatial proteomics and genomics technologies. The acquisition will bring NanoString out of bankruptcy proceedings, providing a swift conclusion to its restructuring process. NanoString's assets were highly sought after, with Bruker's winning bid representing a substantial increase over previous offers.

Illumina Launches TruSight One Sequencing Panel

Illumina introduces the TruSight One Sequencing Panel, boasting the industry's most expansive sequencing panel to date, targeting 4,813 genes known for their associated clinical phenotypes. This versatile panel offers clinical research laboratories numerous benefits, including increased productivity, minimized handling errors, and reduced costs. Illumina's VariantStudio analysis and reporting software further enhances the panel's capabilities, providing advanced annotation and filtering features. The TruSight One Sequencing Panel supports the creation of customizable subpanels, catering to diverse research needs in clinical genetics.

Vizgen New US Patent for MERFISH Technology

Vizgen secures a new US Patent for its MERFISH technology, reinforcing its position as a leader in single-cell spatial genomics. The patent covers the in situ imaging of the spatial transcriptome, facilitating multiplex imaging of RNA and its spatial organization in samples. Terry Lo, CEO of Vizgen, emphasizes the significance of this patent in driving advancements in spatial genomics and improving human health. Despite challenges, including litigation attempts, Vizgen remains committed to scientific innovation and collaboration. The issuance of this patent follows the denial of an Inter Partes Review filed against Vizgen's parent patent, further validating the company's pioneering technology.


Spotlight: Person of the Week - Dr. Daniel Gibson , Co-Founder of Telesis Bio – Revolutionizing Drug Discovery with Enzymatic Synthesis

Dr. Dan Gibson, Co-Founder of Telesis Bio, asserts that their enzymatic synthesis advancements are poised to revolutionize the drug discovery process. They anticipate the generation of mRNA-based vaccine and therapeutic candidates within days instead of weeks or months. Collaborations with partners are viewed as crucial validations of the technology's promise, carrying significant technical and commercial implications. Telesis Bio anticipates substantial future development and commercial milestone payments as evidence of the potential of the Gibson SOLA approach.


Current Live Omics Roles at Kinetica:

?Business Development Manager – Imaging Analysis - West Coast

Business Development Manager – Imaging Analysis – Mid-West

Sales Executive – NGS Software – US

VP of Product Management – Life Science Instruments

Account Manager – Mid-Atlantic – Genomics reagents.

Marketing Manager – Genomics – Northern California

Business Development Manager - Synthetic Biology – West Coast

Business Development Manager - Synthetic Biology – East Coast

Sales Specialist – Spatial Omics – Northeast US

Account Manager – NGS - Northeast US


Job Hunting Tips from an Omics Specialist Recruiter: Seek Mentorship

Finding mentors within the omics community can be incredibly beneficial for your career growth and development. These mentors, who are typically seasoned professionals with extensive experience in the field, can provide invaluable guidance, support, and insights based on their own journeys and successes.

A mentor can offer personalized advice on navigating the complexities of the omics industry, including strategies for advancing your career, overcoming challenges, and identifying opportunities for growth. They can also share their knowledge of emerging trends, technologies, and best practices, helping you stay ahead of the curve and remain competitive in a rapidly evolving field.

In addition to offering professional guidance, mentors can also serve as valuable sounding boards for your ideas and aspirations. They can provide constructive feedback on your career goals, help you identify areas for improvement, and offer encouragement during times of uncertainty or self-doubt.

Moreover, mentorship relationships often extend beyond professional development to include personal support and mentorship. Mentors can offer valuable perspective on work-life balance, managing stress, and nurturing a fulfilling career that aligns with your values and aspirations.

To find a mentor in the omics community, consider reaching out to colleagues, professors, or professionals you admire. Attend industry events, conferences, and networking gatherings where you can connect with potential mentors and initiate meaningful conversations. Remember to approach mentorship as a two-way street, where both parties can learn and grow from each other's experiences and perspectives.


Wrapping Up Another Omics-Insights:

Thank you for embarking on a journey into the dynamic world of Omics with Kinetica! Explore the latest genomics job opportunities, stay informed with industry news, and indulge in insightful blogs at www.kinetica.co.uk. Your curiosity drives my commitment to relevant content, and I'm here to provide insights that fuel your scientific endeavors. Feel free to reach out with any questions or feedback. Wishing you ongoing inspiration and discovery in your scientific pursuits. Until next week, may your experiments yield groundbreaking results, and may your Omics journey remain as fascinating as the science itself!

?

?

?

?

要查看或添加评论,请登录

社区洞察

其他会员也浏览了